Smad proteins are essential components of the signalling cascade initiated by members of the Transforming Growth Factor-b family. TGFb binding to heteromeric complexes of transmembrane Ser/Thr kinases induces Smad2 and Smad3 phosphorylation on their C terminus residues. This phosphorylation leads to oligomerization with Smad4, a common mediator of TGF-b, activin and BMP signalling. The Smad complexes then translocate to the nucleus where they play transcription regulator roles. Even if they share 92% identity, the two TGFb restricted Smad2 and Smad3 are not functionally equivalent. As we have previously shown, Smad3 acts as a transcription factor by binding to a TGFbresponsive sequence termed CAGA box whereas Smad2 does not. Smad2 diers from Smad3 mainly in the Nterminal MH1 domain where it contains two additional stretches of amino acids that are lacking in Smad3. Here, we show that one of these domains corresponding to exon 3 is responsible for the absence of Smad2 transcriptional activity in CAGA box-containing promoters. Furthermore, in vitro studies indicate that this domain prevents Smad2 from binding to this DNA sequence. This suggests that Smad2 and Smad3 may have dierent subsets of target genes participating thus in distinct responses among TGFb pleiotropic eects.
Keywords: Smad; TGFb; transcription; DNA-binding Members of the Transforming Growth Factor-b cytokine family are involved in multiple functions especially in development, production of extracellular matrix and cell cycle regulation (Attisano et al., 1994; Kingsley, 1994) . In particular, TGFb exhibits eects on cell cycle manifested by G1-phase arrest, dierentiation or apoptosis on several target cells such as epithelial cells or B and T lymphocytes, suggesting that disruption of TGFb signalling pathway could be involved in cancer formation (Letterio and Roberts, 1998; White, 1998) . TGFb elicits its eects by binding to a heteromeric complex of transmembrane Ser/Thr kinase receptors known as type I and type II receptors. Upon ligand binding, the type II receptor ± which is constitutively active ± recruits and then phosphorylates the type I receptor in a juxtamembrane domain rich in glycine and serine, the GS domain . Activation of the type I receptor leads to the phosphorylation of various substrates including members of the Mother Against Decapentaplegic family, discovered by genetic studies on Drosophila and C. elegans (Derynck and Feng, 1997; Heldin et al., 1997; Kretschmar and MassagueÂ , 1998) . This family contains nine mammalian members, the Smad proteins, and is divided into three distinct classes. The ®rst one contains pathwayrestricted proteins: Smad1, Smad5 and Smad8 are speci®cally involved in Bone Morphogenetic Protein signalling whereas Smad2 and Smad3 are TGFb/activin pathway-restricted Chen et al., 1997) . After phosphorylation by the receptor, Smads form heteromeric complexes with Smad4, a constitutively phosphorylated common mediator of the two pathways. The Smad complexes then translocate to the nucleus where they control expression of diverse genes (Derynck and Feng, 1997; Dennler et al., 1998; Jonk et al., 1998) . Smad4 is the unique member of the second class of Smad proteins: central ones. The third class includes Smad6 and Smad7 which have been identi®ed as inhibitors of TGFb signalling (Imamura et al., 1997; Hayashi et al., 1997; Nakao et al., 1997; Topper et al., 1997; Hata et al., 1998a) . Interestingly, Smad2 and Smad4 genes are tumor suppressor gene candidates found either deleted or mutated in a number of human cancers including pancreatic and colon carcinomas, providing compelling support for a role of TGFb signalling in the development of some cancers (Hahn et al., 1996; Eppert et al., 1996; Hata et al., 1997 Hata et al., , 1998b Shi et al., 1997) .
All Smad proteins ± except Smad6 and Smad7 ± share two conserved domains termed MH1 and MH2 separated by a non-conserved proline-rich linker (Kretzschmar and MassagueÂ , 1998) . The N-terminus MH1 domain of Drosophila Mad (Kim et al., 1997) , Smad3 and Smad4 (Yingling et al., 1997; Dennler et al., 1998; Zawel et al., 1998) binds DNA and shows no homology with other known DNA binding domains. The C-terminus MH2 domain interacts with the receptor and displays transcriptional activity when fused to a heterologous Gal4 DNA-binding domain (Liu et al., 1996) . It has been proposed that interactions between N-and C-terminus domains of Smad proteins may regulate their transcriptional activity (Liu et al., 1996) . Smad2 and Smad3, the two TGFb pathwayrestricted members of the family, share an overall 92% identity at the amino-acid sequence level. We have previously described an eight nucleotide sequence called the CAGA box found in several promoters and responsible for TGFb responsiveness (Dennler et al., 1998; Jonk et al., 1998) . Remarkably, the TGFbinduced nuclear protein complex that binds to this sequence contains Smad3 and Smad4 but not Smad2 (Dennler et al., 1998) . As shown in Figure 1a After transfection, cells were lysed with the lysis buer provided with the Dual-Luciferase Assay Kit (Promega), proteins were separated on 8.5% SDS ± PAGE then blotted with an anti-Smad2/Smad3 polyclonal antibody (sc-6032, Santa Cruz). Lysates were also immunoblotted with an anti-a-actine polyclonal antibody (sc-1615, Santa Cruz) to assess equal protein loading. The primary antibodies were revealed by chemoluminescence with a secondary antibody coupled to horse peroxidase contains three CAGA boxes (Dennler et al., 1998) . Overexpression of Smad2 protein slightly activates the PAI-1 reporter (62) whereas Smad3 overexpression leads to strong activation (66; data not shown).
We have previously shown that MH1 domain of Smad3 was sucient for speci®c DNA-binding to the CAGA sequence (Dennler et al., 1998) . A comparison between Smad2 and Smad3 MH1 domain reveals that the main dierence is the presence of two stretches of amino acids in Smad2 that are lacking in Smad3 (Figure 2a) . We termed GAG the short N-terminal amino-acid sequence containing ten residues (essentially glycine and serine) comprised between Ser 21 and Gly
30
. The larger sequence, 30 residues long from amino acid Ser 79 to Thr 108 and rich in serine and threonine was called TID. In order to determine whether these sequences are implicated in the lack of transcriptional activity of Smad2, we generated a Smad2 protein deleted in both sequences (Figure 2b ). This mutant transfected in HepG2 cells activated the CAGA reporter to a level comparable with wild type Smad3 (Figure 2c ). This Smad2 DGAG DTID mutant shows that domains GAG or TID are involved in the functional dierence observed between Smad2 and Smad3. In a next step, we tried to determine if this transcriptional dierence could be attributed to a single domain. To address this question, we deleted GAG (Smad2 DGAG) or TID (Smad2 DTID) sequences in Smad2 and tested the eect of mutants on CAGA reporter vector. As shown in Figure 2c , Smad2 DTID mutant was clearly able to activate the CAGA reporter, indicating that the TID domain was involved in the absence of transcriptional ability of Smad2. We could not observe any activation of the CAGA reporter with Smad2 DGAG. However, we could not conclude from this experiment that the GAG domain is not involved in this absence of transcriptional activation since we were unable to detect expression of this mutant by Western blot (Figure 2d) .
In order to complement the results obtained with Smad2 deletion mutant, we introduced the GAG or TID domains in Smad3. In line with the previous data, the Smad3 mutants containing the TID sequence (i.e. Smad3+GAG+TID and Smad3+TID) were unable to activate the CAGA reporter, showing again the implication of this sequence. It is noteworthy that these transcriptionally inactive mutants were expressed in the cells since they were detected in Western blot assays (Figure 2d ). Introduction of the single GAG domain into Smad3 did not modify its transcriptional capacity (see Smad3+GAG, Figure 2c ). These results clearly indicate that the transcriptional dierence observed between Smad2 and Smad3 is due to the single TID domain and not to the GAG sequence. Similar results have been obtained in the context of the natural human PAI-1 promoter reporter vector with clear activation by Smad3, Smad2 DGAG DTID, Smad2 DTID, Smad3+GAG expression and slight or no activation by Smad2, Smad2 DGAG, Smad3+GAG+TID and Smad3+ TID expression in HepG2 cells (data not shown).
The dierence between Smad2 and Smad3 ability to activate transcription may be explained by dierent DNA-binding capacity. Indeed, since the TID domain is responsible for transcriptional dierence between Smad2 and Smad3, it is possible that this domain prevents Smad2 from binding to DNA. In order to verify this hypothesis, we produced the Smad mutant proteins using an in vitro transcription/translation system and tested their DNA-binding capacities in gel shift assays. As shown in Figure 3a , the full length wild-type Smad3, unlike Smad2, bound to the CAGA oligonucleotides. This binding was speci®c since Smad3 was not able to bind to an oligonucleotidic probe containing a version of the CAGA sequence mutated in three nucleotides (Figure 3b ). In agreement with the transfection experiments, Smad2 deleted in both sequences (Smad2 DGAG DTID) and Smad2 DTID were able to bind to the CAGA probe whereas Smad2 DGAG did not. In total correlation with transcriptional activities observed previously, Smad3+GAG bound CAGA oligonucleotides but introduction of TID domain into Smad3 (i.e. Smad3+TID and Smad3+GAG+TID) hindered Smad3 from binding to DNA. Thus, the TID sequence prevents Smad2 from activating transcription by impeding its DNA-binding to the CAGA box.
Despite a 92% identity between the two TGFb pathway-restricted Smad2 and Smad3 proteins, our results and others clearly show that they are not functionally equivalent (Chen Y et al., 1996; Dennler et al., 1998; Zawel et al., 1998) . Here, we report a dierence between Smad2 and Smad3 on the ability to stimulate transcription mediated by the TGFbresponsive CAGA sequence found in several promoters including Plasminogen Activator Inhibitor type I (PAI-1), Collagen a2(I) and JunB promoters (Dennler et al., 1998; Jonk et al., 1998) . Furthermore, our data indicate that this is due to dierences in DNA-binding capacity since in vitro translated full length Smad3 binds to the CAGA sequence whereas Smad2 does not. The main dierence between Smad2 and Smad3 lies in their MH1 domain with two stretches of amino acids termed TID and GAG found only in Smad2. We have demonstrated that the TID sequence, located between Ser 79 and Thr 108 of Smad2 prevents the protein from binding to DNA thus explaining Smad2 inability to activate CAGA-mediated transcription. Since we have submitted this paper, the crystal structure of Smad3 MH1 domain bound to DNA has been published (Shi et al., 1998) . The DNA-binding motif is an 11-residue-long b hairpin embedded in the major groove of DNA. Sequencespeci®c DNA recognition is provided by direct hydrogen bound interactions between DNA bases and amino acid side chains from this b hairpin region. These 11 residues are conserved between all the Smad proteins ± except Smad6 and Smad7. Considering the crystal structure, the TID domain of Smad2 would be located immediately prior to the DNA-binding b hairpin (Shi et al., 1998) . This predicted loop would prevent Smad2 binding to DNA by steric hindrance. Thus, this intrinsic Smad2 characteristic may de®ne the protein as a coactivator interacting with transcriptional factors as FAST-1 (Chen X et al., 1996; Zhou et al., 1998) whereas Smad3 is a transcriptional factor by itself (Dennler et al., 1998; Zawel et al., 1998) .
TGFb potently inhibits growth of several cell types through a number of mechanisms including inhibition of pRB phosphorylation, inhibition of cyclin A and cyclin E production and induction of p21 or p15 cdk inhibitors (Hata et al., 1998b; Hocevar and Howe, 1998) . Mutations of TGFb-signalling pathway components is often observed in cancer cells with a subsequent loss in TGFb-responsiveness. TGFb receptor type II gene mutations occur in a number of colorectal cancers Parsons et al., 1995) . Recently, a signi®cant number of inactivating mutations have been found in SMAD2 and SMAD4 genes in a subset of pancreas or colorectal cancers, establishing their roles as tumor suppressor genes (Hahn et al., 1996; Eppert et al., 1996; Hata et al., 1997; Shi et al., 1997; White, 1998; Kretzschmar and MassagueÂ , 1998) . Recently a Smad2 transcript which lacks exon 3 has been isolated from various human cell lines (Takenoshita et al., 1998; Yagi et al., 1999) but the physiological role of this spliced protein has not been elucidated yet. Our study shows that, due to the presence of TID domain encoded by exon 3, Smad2 is unable to activate transcription through the same CAGA DNA-binding elements than Smad3. Thus it becomes clear now that Smad2 and Smad3 are not redundant proteins but activate transcription in a dierent manner. This could imply that the two proteins have dierent subsets of target genes and control distinct biological responses among the pleiotropic eects of TGFb. Indeed, the fact that the PAI-1 and collagen a2(I) promoters contain CAGA sequences activated by Smad3 and not by Smad2 suggests that Smad3 may be an activator more important than Smad2 for TGFb-regulated extracellular matrix formation. It is also possible that this dierence in transcriptional capacity re¯ects dierent roles for Smad2 and Smad3 in cancer progression. The Smad2 transcript spliced in exon 3 may encode a protein that would activate transcription similarly to Smad3. S-methionine were controlled by SDS ± PAGE and autoradiography before utilization in EMSA. The CAGA box oligonucleotides were end-labelled with a-33 P-dCTP and a-33 P-dATP using the Klenow fragment of DNA polymerase I. Binding reactions containing 16 mL of in vitro translated Smad proteins and 2 ng of labelled oligonucleotide were performed for 20 min at 378C in a ®nal volume of 40 mL of binding buer (20 mM HEPES pH 7.9, 30 mM KCl, 4 mM MgCl 2 , 0.1 mM EDTA, 0.8 mM NaPi, 20% glycerol, 4 mM spermidine, 3 mg poly dI-dC). Protein-DNA complexes were resolved in 5% polyacrylamide gels containing 0.56 TBE. The sequences of the double stranded oligonucleotide used as a probe were: 5'-TCGAGAGCCAGA-CAAAAAGCCAGACATTTAGCCAGACAC-3' and its complementary strand in (a) and 5'-TCGAGAGCTACATAAAAAGC-TACATATTTAGCTACATAC-3' and its complementary strand in (b) 
